[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucagon-like-peptide-1-receptor-agonists\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucagon-like-peptide-1-receptor-agonists":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100598558","phase-4-the-role-of-glucagon-like-peptide-1-receptor-agonists-in-coronary-artery-diseases-and-their-potential-mechanisms-100598558",false,"NCT07073053","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms","Inclusion Criteria:\n\n1. adults (\\>=20 years old),\n2. Type 2 Diabetes with coronary arterial disease underwent angioplasty within 3 months with SGLT2 inhibitors -\n\nExclusion Criteria:\n\n1. age\\\u003C20 years old,\n2. pregnant women,\n3. eGFR\\\u003C30 ml\u002Fmin\u002F1.73m2,\n4. received GLP-1 agonist in the recent 3 months -","ALL","20 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The investigators plan to enroll 60 patients from the outpatient clinics or inpatient wards of the Metabolism and Cardiology departments who, within the past three months, have undergone coronary angiography for the treatment of coronary artery disease, are currently using sodium-glucose cotransporter-2 (SGLT-2) inhibitors for glycemic control, and have not received glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy for more than three months. A randomized controlled clinical trial will be conducted, with 20 participants randomly assigned to receive semaglutide (a GLP-1 RA) at 1 mg once weekly for 6 months, another 20 participants to receive semaglutide at 0.5 mg once weekly for 6 months, and the control group (20 participants) to continue with standard treatment for 6 months. The effects after 6 months will be evaluated in terms of endothelial function, glycemic control indicators including glycemic variability assessed via continuous glucose monitoring (CGM), oxidative stress markers, and the incidence of symptomatic hypoglycemia.\n\nAccording to the treatment guidelines for type 2 diabetes, either GLP-1 receptor agonists or SGLT-2 inhibitors should be prioritized in patients with type 2 diabetes and coronary artery disease. Therefore, the medication choices in both the intervention and control groups in this study align with current treatment guidelines.",[25,26,27],"Glucagon-Like Peptide-1 Receptor Agonists","Type 2 Diabetes","Coronary Arterial Disease (CAD)",[25,29,30],"type 2 diabetes","coronary arterial disease","NOT_YET_RECRUITING","2025-07-09",{"date":34,"type":35},"2025-07-18","ACTUAL",{"date":37,"type":19},"2025-10-01",{"date":39,"type":19},"2028-07-31",{"name":41,"class":42},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100594074","impact-of-glp-1-receptor-agonists-on-patients-with-ipmn-100594074","NCT07014709","Impact of GLP-1 Receptor Agonists on Patients With IPMN","Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study","IPMN-GLP1RA","Inclusion Criteria:\n\n* \\> 18 years old\n* Radiological diagnosis of IPMN\n* Treated with GLP-1 RAs.\n* Patients must have provided prior informed consent for the use of their coded clinical data in research.\n\nExclusion Criteria:\n\n* radiological diagnosis of IPMN is unclear,\n* no documented history of GLP-1 RAs use\n* patients did not provide signed informed consent, or have documented refusal for research.","18 Years",{"count":54,"type":19},30,"OBSERVATIONAL","This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear.\n\nThe study aims to evaluate whether GLP-1 RA use in IPMN patients is linked to changes in pancreatic cyst characteristics, the incidence of acute pancreatitis, variations in tumor markers, and the progression of IPMNs to high-grade dysplasia or malignancy. A retrospective analysis will be conducted using medical data from patients diagnosed with IPMNs and treated with GLP-1 RAs between 2010 and 2024 at three Swiss hospitals. Key outcomes will include radiological changes, the incidence of acute pancreatitis, and potential shifts in IPMN surveillance or need for surgical intervention",[58,59,60,61,25],"IPMN","IPMN, Pancreatic","GLP-1","Intraductal Papillary Mucinous Neoplasm of Pancreas","2025-06-02",{"date":64,"type":35},"2025-06-11",{"date":66,"type":19},"2025-05-31",{"date":68,"type":19},"2026-10-31",{"name":70,"class":71},"Hôpital Fribourgeois","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":15,"minAge":52,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":20,"phases":83,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100556088","phase-1-hdm1002-tablets-in-chinese-overweight-and-obese-adult-subjects-100556088","NCT06520540","HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Oral Administration of HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects","Inclusion Criteria:\n\n1. Chinese subjects aged 18 to 60 years (including 18 years and 60 years old), either male or female subjects;\n2. BMI at 24.0 to 36.0 kg at screening and at random \u002F m2Between (including 24.0 and 36.0 kg \u002F m2）；\n3. For fertile subjects, female subjects from 14 days before the informed consent form (ICF) to 30 days after the last administration, male subjects within 90 days after the ICF to the last administration, without birth planning and agreed to highly effective contraception (see Section 5.2.3 for details);\n4. Ability to understand the procedures and methods of this study, voluntarily sign the ICF, and be willing to strictly comply with the clinical trial protocol requirements to complete the relevant process.\n\nExclusion Criteria:\n\nSelection criteria:\n\nSubjects must meet all of the following inclusion criteria to be enrolled in this study:\n\n1. Chinese subjects aged 18 to 60 years (including 18 years and 60 years old), either male or female subjects;\n2. BMI at 24.0 to 36.0 kg at screening and at random \u002F m2Between (including 24.0 and 36.0 kg \u002F m2）；\n3. For fertile subjects, female subjects from 14 days before the informed consent form (ICF) to 30 days after the last administration, male subjects within 90 days after the ICF to the last administration, without birth planning and agreed to highly effective contraception (see Section 5.2.3 for details);\n4. Ability to understand the procedures and methods of this study, voluntarily sign the ICF, and be willing to strictly comply with the clinical trial protocol requirements to complete the relevant process.\n\nExclusion criteria:\n\nSubjects meeting either of the following criteria will be excluded:\n\n1. 5% self-reported or documented body weight change within 3 months prior to randomization;\n2. Previous diagnosis of type 1, type 2 or any other type of diabetes; or using hypoglycemic drugs; or HbA1c 6.5% at screening or fasting glucose 7.0 mmol\u002FL; or fasting glucose \\\u003C3.9 mmol \u002F L;\n3. Diagnosis of overweight or obesity caused by other diseases or drugs;\n4. History or family history of medullary thyroid carcinoma, thyroid C cell hyperplasia, or multiple endocrine adenomatosis type 2;\n5. History of chronic pancreatitis or onset of acute pancreatitis within 3 months before signing an ICF;\n6. History of acute gallbladder disease within 3 months before signing the ICF;\n7. Any malignant tumor within 5 years before signing the ICF (except for basal cell carcinoma that has received curative treatment and is considered cured);\n8. Combination of cardiovascular and cerebrovascular diseases with obvious clinical significance, including but not limited to angina pectoris, MI, stroke or severe peripheral artery circulation disorder within 1 year before signing ICF; presence of risk factors of torsade ventricular tachycardia; presence of untreated serious arrhythmia, such as sick sinus syndrome, second or third degree atrioventricular block; or screening systolic blood pressure 160 mmHg, or diastolic blood pressure 100 mmHg;\n9. In the judgment of the investigator, the subjects had some diseases or conditions that may affect drug absorption, such as active inflammatory bowel disease, gastrectomy resection, any intestinal area resection, etc.;\n10. Those who had major surgery within 3 months prior to signing the ICF or who performed surgery during the planned study;\n11. According to the investigator, the presence of concomitant diseases, including but not limited to the respiratory system, digestive system, nervous system, urogenital system, blood system, endocrine system and other diseases;\n12. Known intolerance or hypersensitivity to a GLP-1 receptor (GLP-1R) agonist;\n13. Within 3 months prior to ICF signing, the following drugs were used and significantly weight, including but not limited to: a. Drugs or products with weight loss effects, such as GLP-1R agonists (liraglutide, selmeaglutide, benallutide, etc.), orlistat, naltrexone \u002F bupropion, etc.; b. Drugs or products that increase body weight, such as systemic corticosteroids, psychiatric medication (e. g., tricyclic antidepressants, paroxetine, olanzapine, clozapine, mirtazapine, valproic acid and its derivatives, etc.); c. Any Chinese patent medicine or Chinese herbal medicine that may affect the body weight;\n14. Any drug used within 14 days or may affect the pharmacokinetics of HDM1002 tablets (whichever is older) (see Section 6.4.2 and Section 6.4.3), including prescription drugs, over-the-counter drugs, Chinese herbal medicines, proprietary Chinese medicines, or nutritional supplements;\n15. Subjects taking lipid-lowering drugs within 30 days before signing ICF;\n16. Have participated in any clinical trial within 30 days before randomization or within 5 half-lives after the last dose (whichever is older) (except for signed ICF with no drug or device intervention);\n17. Any of the laboratory indicators during the screening period met the following criteria:\n\n    1. \\\u003C110 g \u002F L for women and \\\u003C120 g \u002F L for men;\n    2. glutamate aminotransferase\\> 2.0 upper limit of normal (ULN), or aminotransferase\\> 2.0 ULN, or alkaline phosphatase\\> 1.5 x ULN, or total bilirubin\\> 1.5 ULN (subjects with Gil bert's syndrome can participate in this study with direct bilirubin ULN);\n    3. Triglycerides\\> 5.6 mmol \u002F L;\n    4. Calcitonin: 35 ng\u002FL;\n    5. Thyroid-stimulating hormone\\> 6.0 mIU \u002F L or \\\u003C0.4 mIU \u002F L;\n    6. Blood amylase or lipase\\> ULN;\n    7. Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m, calculated from the Cooperative Epidemiological Study of Chronic Kidney Disease (CKD-EPI) formula2；\n18. The following ECG abnormalities were present during the screening period: QTcF\\> 450 ms, or heart rate \\\u003C50 beats \u002F min or\\> 100 beats \u002F min;\n19. Positive test results for hepatitis B virus surface antigen, hepatitis C virus antibody or treponema pallidum antibody, or non-negative for human immunodeficiency virus;\n20. More than 5 cigarettes per day in the 3 months before signing the ICF;\n21. Those who had drunk alcohol abuse within 1 year before signing the ICF (i. e., drinking more than 14 standard units per week for men, women drinking more than 7 standard units per week, 1 standard unit containing 14 g alcohol, such as 360 ml beer or 150 ml alcohol of 40 ml), or prerandomized alcohol breath test or blood alcohol test positive;\n22. History of addictive drug abuse within 1 year before signing the ICF, or positive urine drug test before randomization;\n23. Within 7 days prior to randomization, subjects reported having consumed grapefruit or products containing grapefruit;\n24. Pregnancy (blood human chorionic gonadotropin 5 mIU \u002F ml or positive urine pregnancy test) or lactating women;\n25. The subject is the investigator or other relevant investigator of the project;\n26. In the opinion of the investigator, the subject was not fit to participate in any other condition of the trial.",true,"60 Years",{"count":82,"type":19},72,[84],"PHASE1","• To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.",[25],[25,88,89],"HDM1002 tablet","Chinese overweight and obese adult","2024-07-20",{"date":92,"type":35},"2024-07-25",{"date":94,"type":19},"2024-07-28",{"date":96,"type":19},"2024-12-30",{"name":98,"class":99},"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","INDUSTRY"]